creat bluematrix
buy new antibodi paradigm initi coverag buy
rate pt
messag initi coverag inc buy rate pt compani pioneer
research develop igm class antibodi hold promis differenti tradit igg antibodi
may also overcom histor difficulti recombin express effici manufactur igm therapeut
class lead product read initi clinic data t-cell engag design
potenti differenti clinic profil compar current emerg igg-bas t-cell engag lower rate
side-effect well activ patient low target express second advanc program target
potenti overcom on-going difficulti trigger strong apoptot signal tumor cell guid ind file
earli pipelin consist addit t-cell engag receptor cross-link agonist gitr
target cytokin long-term valu driver
rate buy pt earli stage biotech compani dilut market cap focus
develop therapeut igm antibodi within oncolog compani claim overcom histor difficulti
recombin express effici manufactur engin stymi past industri invest class
therapeut success igm antibodi class could penetr ww anti-canc antibodi market potenti worth bn
accord evaluatepharma consensu current domin tradit igg igg-bas technolog
antibody-drug conjug bispecif lead product bispecif igm phase clinic trial preclin
data suggest differenti profil includ potenti enhanc efficaci analogu igg t-cell engag well minim
cytokin releas syndrom seriou advers event associ t-cell engag compani also earli pipelin
consist igm antibodi target death receptor expect undergo ind file multipl preclinical-stag
asset includ t-cell engag bispecif acut myeloid leukemia aml multipl myeloma
mm respect receptor cross-link agonist target gitr undisclos group target cytokin target
valuat consist attribut potenti relaps refractori b-cell malign balanc
estim cash year valu share bull case scenario gmab hexabodi readout provid
potenti extern valid igm success undergon ind file initi clinic readout
posit readout includ clean safeti profil littl sign competit efficaci vs t-cell engag
bear case scenario igm-bas platform read disappoint data see stock trade near cash level
lead product bispecif igm potenti clinic differenti improv
potenc b-cell malign improv safeti via mitig therapeut field b-cell malign
becom increasingli crowd multipl t-cell engag clinic develop
mosunetuzumab rog-sw gmab well approv late-stag product
mechan action polatuzumab rog-sw tafasitamab mor-d said believ lead product hold
promis offer differenti profil exist t-cell engag engin igm bind site
site contrast current emerg igg-bas t-cell engag ratio bind
present preclin data suggest minim use igm-bas t-cell engag contrast current emerg
igg approach neurotox common toxic associ t-cell engag result clinic hold
page analyst certif import disclosur
patient death program cancel well protocol adjust clinic monitor manag symptom t-
cell engag phase design could also potenti signal fda appar comfort allow singl patient
dose escal cohort much rapid design usual conserv mabel minimum anticip biolog effect level
approach typic use igg t-cell engag furthermor preclin data point potenti improv efficaci rituxan
rog-sw bispecif igg analogu igm format demonstr better bind cell kill rituxan-resist cell
igm could potenti overcom histor difficulti trigger tumor cell apoptosi via prior agonist
shown minim clinic benefit potenti due inadequ cross-link requir strong apoptot signal tradit igg
format engag two receptor recent approach util multival construct though recent readout
tetraval novn inhibrx hexaval construct includ modest activ
said potenti competitor gmab dodecaval bind site agonist report case studi earli
patient respond prior line therapi compani guid ye updat could serv extern
valid approach see gmab initi
earli discoveri pipelin could potenti valu driver longer term addit igm compani
highlight multipl preclin program classifi one three categori t-cell engag compani
highlight bispecif acut myeloid leukemia bispecif multipl myeloma receptor cross-link agonist
compani develop two distinct igm antibodi target gitr target cytokin compani
multipl bispecif yet disclos current attribut valu earli pipelin posit data
current lead program may serv potenti valid igm therapeutic-bas approach read posit
base-cas valuat scenario forecast peak ww probability-adjust po sale
model peak market penetr relaps refractori dlbcl fl given potenti competit dynam via
target igg t-cell engag like becom commerci prior off-set potenti differenti
clinic profil view could promot market adopt also assum launch year month net price per
patient month durat therapi assumpt r/r dlbcl fl potenti revenu indic beyond
r/r dlbcl fl could repres potenti upsid current estim valuat includ pipelin asset
valuat current view potenti sourc longer term upsid
upcom potenti stock catalyst pipelin event lead candid recent dose first patient on-going phase
dose escal expect read initi clinic data meantim potenti competitor igg-bas
bispecif gmab mosunetuzumab rog-sw read clinic result around
time initi pivot phase ii r/r dlbcl guid file ind antibodi
program could see read-through hexabodi gmab target initi data updat similar
multival target engag approach igm
page analyst certif import disclosur
initi coverag igm bioscienc
page analyst certif import disclosur
page analyst certif import disclosur
tabl content
page analyst certif import disclosur
compani profil execut
page analyst certif import disclosur
rate buy earli clinical-stag biotech
compani platform focus therapeut igm
antibodi igm antibodi possess advantag tradit igg
multival overcom histor limit
igm manufactur becom pioneer leader field
see valu driver stock lead candid
bispecif t-cell engag potenti differenti profil
enhanc safeti potenc rel t-cell engag
preclin igm may overcom histor limit
signal tumor cell death via death receptor earli
pipelin addit igm-bas therapeut
clinic valid igm antibodi format level
potenti improv tradit igg antibodi
potenti emerg competit platform
hexabodi gmab-dc
valu upsid potenti earli pipelin
ind submiss igm
phase dose escal data
chart slide overal market perform
page analyst certif import disclosur
clinical-stag biotech compani pioneer igm-bas oncolog therapeut compani proprietari method
overcom histor difficulti effici manufactur igm antibodi technolog platform focus antibodi engin
approach exploit potenti advantag igm tradit igg address unmet need medic oncolog
lead clinic candid potenti differenti asset field multipl bispecif unlik tradit
igg-bas t-cell engag igm format expect exhibit lower level cytokin releas syndrom time exhibit
enhanc on-target potenc improv safeti efficaci igm potenti enhanc cluster death receptor subsequ
apoptot signal could overcom histor barrier effect therapeut signal also earli pipelin
consist addit igm-bas t-cell engag receptor cross-link agonist target cytokin
page analyst certif import disclosur
bull highli promis differenti
igm advantag tradit igg-bas
consider market antibodi market potenti
mitig cytokin releas syndrom rel
pioneer igm engin uniqu
differenti platform rel current competitor
bear early-stag technolog platform
igm antibodi therapeut class yet de-
risk current approv
potenti level clinic improv tradit
approach abil drive market uptake/shar
valid could also lead competit overhang
highli promis differenti platform base
engin igm-bas therapeut lead
pioneer develop igm-bas antibodi cancer
therapeut preclin data thu far highlight key point
potenti differenti tradit igg-bas antibodi
mitig cytokin releas t-cell engag
potenti multival interact receptor
potenti competitor catalyst could serv extern
valid head clinic readout potenti
competitor gmab conduct clinic trial
could serv potenti extern valid
multival approach toward target may requir
cross-link propag apoptot signal tumor
earli pipelin consist igm-bas t-cell engag
receptor cross-link agonist target cytokin
repres potenti upsid current includ
earli pipelin part valuat potenti posit news
flow lead candid igm could serv
valid igm-bas technolog platform read-
posit earli pipelin
page analyst certif import disclosur
per dcf
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
po
penetr r/r dlbcl fl market
valu pipelin agent
posit initi readout littl clean
safeti sign efficaci look competit vs
extern valid potenti posit hexabodi
compani execut develop igm
success ind file phase initi
disappoint readout point limit
clinic differenti suggest inferior vs igg-bas
neg read-through igm
valu attribut earlier pipelin
compani trade cash
page analyst certif import disclosur
ceo member igm board director sinc
former manag charter life scienc vc firm
former ceo chairman board heska corpor
cso sinc
former trelli bioscienc
prior preclin role abmaxi abgenix millenium roch
sinc
former global head cancer immunotherapi roch
former franchis develop lead tecentriq
cfo sinc
prior financ role dermira onyx human genom scienc
former manag consult oliv wyman
page analyst certif import disclosur
initi coverag biotechnolog stock focus
igm-bas therapeut subset innov antibodi platform repres major categori
among emerg oncolog compani see initi ftsv mru
weve previous highlight four innov oncolog area think well-posit see coverag launch next-gen antibodi platform
initi includ precis oncolog antibody-drug conjug cell immunotherapi next-gen antibodi platform
igm antibodi scientif clinic interest given naturally-occur may possess advantag igg
histor challeng recombin express manufactur igm hinder industri develop therapeut class
current valuat in-lin among peer group earli clinical-stag biotechnolog compani
guggenheim secur llc analysi compani websit mcap ev estim factset consensu
page analyst certif import disclosur
tickermcap ev preclinicalphas iphas iiph pioneer develop therapeut igm antibodi
possess sever potenti advantag tradit igg
structur comparison tradit igg vs engin igm
natur function igm human
natur igm tend first respond immun
respons low affin broad specif rapid
express contrast igg innat immun
may act bridg innat adapt
immun bring antigen lymphoid organ
potenti advantag igm antibodi format
multival vs bival igg interact lead better
target cancer cell particularli low expressor
abil bind glycoprotein carbohydrate-bas
target expand potenti rang therapeut target
crosslink cell surfac receptor may enhanc
signal receptor-medi pathway
platform bring clinic
overcom tradit difficulti scale
express manufactur igm antibodi
protein engin technolog allow modif igm
antibodi possess featur relev benefici
page analyst certif import disclosur
oncolog antibodi market worth
page analyst certif import disclosur
valu driver target earli pipelin
per dcf
npv
contribut valuat
po assumpt b-cell malign
assum us incid r/r dlbcl
assum us incid r/r fl
market share assumpt r/r dlbcl fl
initi phase trial data guid
includ valuat potenti long-term upsid
assum bn ww peak sale achiev
 acut myeloid leukemia
potenti overcom histor difficulti promot anti-
 multipl myeloma
cancer signal death receptor
may differenti potenti competitor gmab-dc
hexabodi first-mov advantag among multival ab
ind file expect igm
target cytokin igm
potenti upsid current includ valuat
page analyst certif import disclosur
clinically-valid target
express sever tumor type
express b-cell malign
t-cell engag bind t-cell
target ligand similar
 t-cell engag antibodi
convent igg ineffect due
 igm aml
igg format clinic poc efficaci
first-in-class molecul
associ target
read initi clinic data
lack receptor polymer limit
igg bind maximum ligand
clinically-valid target
could promot receptor
 igm myeloma
clinically-valid target darzalex
gmab-dc could serv extern
format promot receptor cluster
signal target includ gitr
guidanc ind igm
target cytokin deliv cytokin
t-cell enhanc tumor activ
share r/r dlbcl/fl po
given lack clinic data valid
cautiou histor challeng
current limit line sight given earli
drug unknown multival
lead clinic benefit potenti
igm success upsid valuat
potenti earli pipelin success
upsid current valuat
page analyst certif import disclosur
estim peak ww revenu po market
opportun r/r dlbcl fl
us pos-adjust revenu forecast
annual r/r b-cell malign patient us
po r/r dlbcl
po r/r fl
treatment candid therapi
launch year r/r dlbcl fl
share r/r dlbcl fl
net price launch annual increas
guggenheim secur llc estim analysi
page analyst certif import disclosur
page analyst certif import disclosur
 financi
page analyst certif import disclosur
incom statement sales- collabor revenue- royalties- total revenues- cogs- total cost oper incom interest income- interest expense- incom incom incom tax- net incom dilut ep per share outstand bs cf debt- guggenheim secur llc estim sec file
page analyst certif import disclosur
clinically-valid target
express sever tumor type
express b-cell malign
t-cell engag bind t-cell
target ligand similar
 t-cell engag antibodi
convent igg ineffect due
 igm aml
igg format clinic poc efficaci
first-in-class molecul
associ target
read initi clinic data
lack receptor polymer limit
igg bind maximum ligand
clinically-valid target
could promot receptor
 igm myeloma
clinically-valid target darzalex
gmab-dc could serv extern
format promot receptor cluster
signal target includ gitr
guidanc ind igm
target cytokin deliv cytokin
t-cell enhanc tumor activ
share r/r dlbcl/fl po
given lack clinic data valid
cautiou histor challeng
current limit line sight given earli
drug unknown multival
lead clinic benefit potenti
igm success upsid valuat
potenti earli pipelin success
upsid current valuat
page analyst certif import disclosur
target t-cell engag antibodi valid approach
multipl candid clinic pipelin
on-going bispecif igg program b-cell malign
ex-r/r dlbcl fl-onli
ae
guggenheim secur llc analysi sec file websit eha icml compani present press releas
page analyst certif import disclosur
target t-cell engag antibodi valid approach
multipl candid clinic pipelin
guggenheim secur llc analysi sec file websit eha icml compani present press releas
page analyst certif import disclosur
potenti mitig could potenti differenti first-in-class
product crowd field t-cell engag
could mitig rel igg t-cell engag
rate advers event
gr
mosunetuzumab mg
mgnx/jnj discontinu partial
due toxic concern
clinic hold death
partial clinic hold due
partial clinic hold
report death patient studi
 combo trial due
exhibit almost non-human primat
page analyst certif import disclosur
multival bind could potenti address tumor low
level express address igg
better vitro igm bind vs igg
better vitro igm cell kill vs igg
activ rituxan-resist cell
page analyst certif import disclosur
rapid dose escal seek quickli valid igm could
mitig initi result guid
follow design
escal cohort
enrol r/r dlbcl r/r fl
page analyst certif import disclosur
potenti competit benchmark r/r dlbcl
action
mpf mo reach
mpf mo reach
mg dose cohort
mg dose cohort
page analyst certif import disclosur
potenti competit benchmark r/r fl
action
mpf mo reach
os year
os year
mpf mo reach
mg dose cohort
mg dose cohort
page analyst certif import disclosur
